Integrative Modeling Strategies for Predicting Drug Toxicities at the eTOX Project

Molecular Informatics

Volumn 34, Issue 6-7, 2015, Pages 477-484

  Sanz, Ferran ^a   Carriõ, Pau ^a   Lõpez, Oriol ^a   Capoferri, Luigi ^b   Kooi, Derk P ^b   Vermeulen, Nico P E ^b   Geerke, Daan P ^b   Montanari, Floriane ^c   Ecker, Gerhard F ^c   Schwab, Christof H ^d   Kleinöder, Thomas ^d   Magdziarz, Tomasz ^d   Pastor, Manuel ^a  

^a UNIVERSITAT POMPEU FABRA   (Spain)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c UNIVERSITY OF VIENNA   (Austria)

^d Molecular Networks GmbH   (Germany)

Author keywords

AOP; Drug safety; Integrative modeling; Multi scale models; Toxicity prediction

Indexed keywords

DRUG;

ARTICLE; DECISION TREE; DRUG SAFETY; INFORMATION MODEL; LIPIDOSIS; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; ADVERSE DRUG REACTION; ANIMAL; BIOLOGICAL MODEL; HUMAN; MOLECULAR DYNAMICS;

ANIMALS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; MODELS, BIOLOGICAL; MOLECULAR DYNAMICS SIMULATION;

EID: 84933520162     PISSN: 18681743     EISSN: 18681751     Source Type: Journal    
DOI: 10.1002/minf.201400193     Document Type: Article

References (53)

1. L. V Sacks, H. H. Shamsuddin, Y. I. Yasinskaya, K. Bouri, M. L. Lanthier, R. E. Sherman, JAMA 2014, 311, 378-384.
2. J. A. Kramer, J. E. Sagartz, D. L. Morris, Nat. Rev. Drug Discov. 2007, 6, 636-649.
3. DSSTox, http://www.epa.gov/ncct/dsstox/.
4. ACToR, http://actor.epa.gov/actor/faces/ACToRHome.jsp.
5. A. Kopp-Schneider, P. Prieto, A. Kinsner-Ovaskainen, S. Stanzel, Toxicol. In Vitro 2013, 27, 1395-1401.
6. F. Shah, N. Greene, Chem. Res. Toxicol. 2014, 27, 86-98.
7. R. Kavlock, K. Chandler, K. Houck, S. Hunter, R. Judson, N. Kleinstreuer, T. Knudsen, M. Martin, S. Padilla, D. Reif, et al., Chem. Res. Toxicol. 2012, 25, 1287-1302.
8. M. S. Attene-Ramos, N. Miller, R. Huang, S. Michael, M. Itkin, R. J. Kavlock, C. P. Austin, P. Shinn, A. Simeonov, R. R. Tice, Drug Discov. Today 2013, 18, 716-723.
9. B. Hardy, N. Douglas, C. Helma, M. Rautenberg, N. Jeliazkova, V. Jeliazkov, I. Nikolova, R. Benigni, O. Tcheremenskaia, S. Kramer, et al., J. Cheminform. 2010, 2.
10. R. Benigni, C. L. Battistelli, C. Bossa, O. Tcheremenskaia, P. Crettaz, Mutagenesis 2013, 28, 401-409.
11. I. Tluczkiewicz, M. Batke, D. Kroese, H. Buist, T. Aldenberg, E. Pauné, H. Grimm, R. Kühne, G. Schüürmann, I. Mangelsdorf, et al., Regul. Toxicol. Pharmacol. 2013, 67, 157-169.
12. Safe-T, http://www.imi-safe-t.eu/.
13. eTOX, http://etoxproject.eu/.
14. K. Briggs, M. Cases, D. J. Heard, M. Pastor, F. Pognan, F. Sanz, C. H. Schwab, T. Steger-Hartmann, A. Sutter, D. K. Watson, et al., Int. J. Mol. Sci. 2012, 13, 3820-46.
15. M. Cases, K. Briggs, T. Steger-Hartmann, F. Pognan, P. Marc, T. Kleinöder, C. H. Schwab, M. Pastor, J. Wichard, F. Sanz, Int. J. Mol. Sci. 2014, 15, 21136-54.
16. M. E. B. Meek, H. a. Barton, J. G. Bessems, J. C. Lipscomb, K. Krishnan, Regul. Toxicol. Pharmacol. 2013, 66, 116-29.
17. M. Vinken, Toxicology 2013, 312, 158-165.
18. Organisation for Economic Co-Operation and Development (2007) Guidance Document on the Validation of (Quantitative) Structure-Activity Relationships [(Q)SAR] Models. Report Number ENV/JM/MONO, 2007.
19. P. Carriõ, O. Lõpez, F. Sanz, M. Pastor, J. Cheminform. 2015, 7, 8.
20. F.L. Atkinson, Standardiser, https://github.com/flatkinson/standardiser.
21. M. Baroni, G. Costantino, G. Cruciani, D. Riganelli, R. Valigi, S. Clementi, Quant. Struct. Relationships 1993, 12, 9-20.
22. P. Carriõ, M. Pinto, G. Ecker, F. Sanz, M. Pastor, J. Chem. Inf. Model. 2014, 54, 1500-1511.
23. M. Berthold, N. Cebron, F. Dill, T. Gabriel, T. Kötter, T. Meinl, P. Ohl, C. Sieb, K. Thiel, B. Wiswedel, in Data Anal. Mach. Learn. Appl. SE-38 (Eds:, C. Preisach, H. Burkhardt, L. Schmidt-Thieme, R. Decker,), Springer, Heidelberg, 2008, pp.319-326.
24. Pipeline Pilot
25. C. Obiol-Pardo, J. Gomis-Tena, F. Sanz, J. Saiz, M. Pastor, J. Chem. Inf. Model. 2011, 51, 483-492.
26. K. Tomizawa, K. Sugano, H. Yamada, I. Horii, J. Toxicol. Sci. 2006, 31, 315-24.
27. Z. Hruban, Environ. Health Perspect. 1984, 55, 53-76.
28. M. Pastor, G. Cruciani, I. McLay, S. Pickett, S. Clementi, J. Med. Chem. 2000, 43, 3233-43.
29. Á. Durán, G. C. Martínez, M. Pastor, J. Chem. Inf. Model. 2008, 48, 1813-1823.
30. N. L. Kruhlak, S. S. Choi, J. F. Contrera, J. L. Weaver, J. M. Willard, K. L. Hastings, L. F. Sancilio, Toxicol. Mech. Methods 2008, 18, 217-227.
31. F. Milletti, L. Storchi, G. Sforna, S. Cross, G. Cruciani, J. Chem. Inf. Model. 2009, 49, 68-75.
32. F. Milletti, L. Storchi, G. Sforna, G. Cruciani, J. Chem. Inf. Model. 2007, 47, 2172-81.
33. J. J. Sutherland, L. O'Brien, D. F. Weaver, J. Med. Chem. 2004, 47, 5541-54.
34. Á. Durán, M. Pastor, Pentacle, http://www.moldiscovery.com/software/pentacle.
35. J. Aqvist, C. Medina, J. E. Samuelsson, Protein Eng. 1994, 7, 385-391.
36. L. Peric-Hassler, E. Stjernschantz, C. Oostenbrink, D. P. Geerke, Int. J. Mol. Sci. 2013, 14, 24514-24530.
37. C. R. Vosmeer, R. Pool, M. F. Van Stee, L. Peric-Hassler, N. P. E. Vermeulen, D. P. Geerke, Int. J. Mol. Sci. 2014, 15, 798-816.
38. E. Stjernschantz, C. Oostenbrink, Biophys. J. 2010, 98, 2682-2691.
39. A. Jakalian, B. L. Bush, D. B. Jack, C. I. Bayly, J. Comput. Chem. 2000, 21, 132-146.
40. R. Meier, M. Pippel, F. Brandt, W. Sippl, C. Baldauf, J. Chem. Inf. Model. 2010, 50, 879-889.
41. J. Hritz, A. De Ruiter, C. Oostenbrink, J. Med. Chem. 2008, 51, 7469-7477.
42. P. Vasanthanathan, J. Hritz, O. Taboureau, L. Olsen, F. S. Jørgensen, N. P. E. Vermeulen, C. Oostenbrink, J. Chem. Inf. Model. 2009, 49, 43-52.
43. A. W. Sousa, W. F. Vranken, BMC Res. Notes 2012, 5, 367.
44. B. Hess, C. Kutzner, D. Van Der Spoel, E. Lindahl, J. Chem. Theory Comput. 2008, 4, 435-447.
45. R. J. Vaz, A. Nayeem, K. Santone, G. Chandrasena, A. V. Gavai, Bioorganic Med. Chem. Lett. 2005, 15, 3816-3820.
46. L. H. Cohen, M. J. Remley, D. Raunig, A. D. N. Vaz, Drug Metab. Dispos. 2003, 31, 1005-1015.
47. L. E. Korhonen, M. Rahnasto, N. J. Mähönen, C. Wittekindt, A. Poso, R. O. Juvonen, H. Raunio, J. Med. Chem. 2005, 48, 3808-3815.
48. Guidance for Industry, Drug Interaction Studies-Study Design, Data Analysis, and Implications for Dosing and Labeling Recommendations, Food and Drug Administration, 2012.
49. C. M. F. Kruijtzer, J. H. Beijnen, H. Rosing, W. W. ten Bokkel Huinink, M. Schot, R. C. Jewell, E. M. Paul, J. H. M. Schellens, J. Clin. Oncol. 2002, 20, 2943-2950.
50. F. Montanari, G. F. Ecker, Mol. Inform. 2014, 33, 322-331.
51. G. Landrum, RDKit: Open-source cheminformatics, http://www.rdkit.org.
52. F. Pedregosa, G. Varoquaux, A. Gramfort, V. Michel, B. Thirion, O. Grisel, M. Blondel, P. Prettenhofer, R. Weiss, V. Dubourg, et al., J. Mach. Learn. Res. 2012, 12, 2825-2830.
53. GPL v3, http://www.gnu.org/copyleft/gpl.html.